Suppr超能文献

使用等效性测试方法对配体结合分析的关键试剂进行资格认证的案例研究。

A Case Study for Critical Reagent Qualification for Ligand Binding Assays Using Equivalence Test Methodology.

机构信息

Battelle Health Analytics, Columbus, OH, USA.

Battelle Biomedical Research Center, West Jefferson, OH, USA.

出版信息

AAPS J. 2023 Sep 15;25(5):89. doi: 10.1208/s12248-023-00857-8.

Abstract

Qualifying critical reagents in ligand binding assays by parallel testing of current and candidate reagent lots is recommended by regulatory agencies and industry groups, but specific guidance on the format of reagent qualification experiments is limited. Equivalence testing is a statistically sound approach that is consistent with the objective of critical reagent qualification. We present power analysis for equivalence regions ranging from 1.25- to 1.5-fold multiples of the GM ratio (centered on 1) of current and candidate lots, over a range of assay variability from 5 to 30% coefficient of variation (CV). A 1.25-fold equivalence region can be tested using 6 to 12 plates per lot for assays with up to 15% CV but is not practical for more variable assays. For these assays, wider equivalence regions are justified so long as care is taken to avoid assay drift and the assay remains suitable for the intended use. The equivalence test method is illustrated using historical data from passing and failing reagent qualification experiments. Simulation analysis was performed to support the design of qualification experiments using 6, 12, or 18 plates per lot over a broad range of assay variability. A challenge in implementing the equivalence test approach is selecting an appropriate equivalence region. Equivalence regions providing 90% power using 12 plates/lot were consistent with 1.5σ bounds, which are recommended for equivalence testing of critical quality attributes of biosimilars.

摘要

通过对当前和候选试剂批次进行平行测试来对配体结合测定法中的关键试剂进行质量确认,这一方法得到了监管机构和行业团体的推荐,但是关于试剂质量确认实验的具体指导却十分有限。等效性检验是一种合理的统计学方法,与关键试剂质量确认的目标一致。我们提出了在变异系数(CV)为 5%至 30%的范围内,当前和候选批次的 GM 比值(以 1 为中心)的 1.25 至 1.5 倍等效区间的功效分析。对于 CV 不超过 15%的测定法,可以使用每批 6 至 12 个板来进行 1.25 倍等效区间的检验,但对于更具变异性的测定法来说并不实用。对于这些测定法,只要小心避免测定漂移并使测定法仍然适用于预期用途,更宽的等效区间是合理的。等效性检验方法使用通过和未通过的试剂质量确认实验的历史数据进行了说明。通过模拟分析,支持了在 CV 广泛变化的情况下,每批使用 6、12 或 18 个板进行质量确认实验的设计。实施等效性检验方法的一个挑战是选择合适的等效区间。使用 12 个板/批提供 90%功效的等效区间与建议用于生物类似药关键质量属性等效性检验的 1.5σ 边界一致。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验